The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines

Molecular and Cellular Biochemistry

Volumn 390, Issue 1-2, 2014, Pages 271-280

  Chen, Ruo Chan ^a   Yi, Pan Pan ^a   Zhou, Rong Rong ^a   Xiao, Mei Fang ^a   Huang, Ze Bing ^a   Tang, Dao Lin ^b   Huang, Yan ^a   Fan, Xue Gong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Hepatocellular carcinoma; HMGB1; Invasion; Migration; RAGE

Indexed keywords

ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; SMALL INTERFERING RNA;

CELL MOTION; CELL PROLIFERATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HMGB1 PROTEIN; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84898910879     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-1978-6     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Yan W, Chang Y, Liang X et al (2012) High-mobility group box1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55:1863-1875
3. Basta GNT, De Simone P, Del Turco S et al (2011) What is the role of the receptor for advanced glycation end products-ligand axis in liver injury? Liver Transpl 17:633-640
4. Taguchi A, Blood DC, del Toro G et al (2000) Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:354-360
5. Neeper M, Schmidt AM, Brett J et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004
6. Schmidt AMVM, Gerlach M, Brett J et al (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997
7. Volp K, Brezniceanu ML, Bosser S et al (2006) Increased expression of high mobility group box1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 55:234-242
8. Sims GP, Rowe DC, Rietdijk ST et al (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28:367-388
9. Jarnagin W, Chapman WC, Curley S et al (2010) Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 12:302-310
10. Yaser AM, Huang Y, Zhou RR et al (2012) The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int J Mol Sci 13:5982-5997
11. Aradhya S, Nelson DL (2001) NF-kappaB signaling and human disease. Curr Opin Genet Dev 11:300-306
12. Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7-11
13. Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107:3-6
14. Cho HAPI, Kim TW, Oh YK et al (2009) Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res 32:1077-1086
15. Wang C, Lu Y, Chen Y et al (2009) Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study. Clin Exp Metastasis 26:839-848
16. Okamoto T, Sanda T, Asamitsu K (2007) NF-kappa B signaling and carcinogenesis. Curr Pharm Des 13:447-462
17. He Q, You H, Li XM et al (2012) HMGB1 promotes the synthesis of Pro-IL-1β and pro-IL-18 by activation of p38 MAPK and NF-κB through receptors for advanced glycation end-products in macrophages. Asian Pac J Cancer Prev 13:1365-1370
18. Sasahira T, Kirita T, Oue N et al (2008) High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci 99:1806-1812
19. Shi GM, Ke AW, Zhou J et al (2010) CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 52:183-196
20. Li Y, Tang ZY, Ye SL et al (2001) Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 7:630-636
21. Li Y, Tang Y, Ye L et al (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129:43-51
22. DeNardo DG, Andreu P, Coussens LM (2010) Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev 29:309-316
23. Lotze MT, Tracey KJ (2005) High-mobility group box1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342
24. Tang D, Kang R, Zeh HJ et al (2010) High-mobility group box1 and cancer. Biochim Biophys Acta 1799:131-140
25. Krysko O, Love Aaes T, Bachert C et al (2013) Many faces of DAMPs in cancer therapy. Cell Death Dis 4:e631
26. Yang H, Rivera Z, Jube S et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box1 protein release and resultant inflammation. Proc Natl Acad Sci USA 107:12611-12616
27. Zhou RR, Zhao SS, Zou MX et al (2011) HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol 11:21
28. Jiang W, Wang Z, Li X et al (2012) High-mobility group box1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol Oncol Res 18:293-298
29. Jung JH, Park JH, Jee MH et al (2011) Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J Virol 85:9359-9368
30. Geroldi D, Falcone C, Emanuele E et al (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23:1725-1729
31. Tesarova P, Kalousova M, Jachymova M et al (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25:720-725
32. Jang Y, Kim JY, Kang SM et al (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56:199-205
33. Kalea AZ, See F, Harja E et al (2010) Alternatively spliced RAGEv1 inhibits tumorigenesis through suppression of JNK signaling. Cancer Res 70:5628-5638